Royalty Pharma plc (MUN:RPD)
Germany
· Delayed Price · Currency is EUR 33.50
-0.56 (-1.64%)
At close: Jan 2, 2026
Royalty Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Revenue | 2,378 | 2,264 | 2,355 | 2,237 | 2,289 | Upgrade
|
| Revenue Growth (YoY) | 5.06% | -3.86% | 5.24% | -2.28% | 7.87% | Upgrade
|
| Cost of Revenue | -295.84 | 732.46 | 560.66 | 904.24 | 452.84 | Upgrade
|
| Gross Profit | 2,674 | 1,531 | 1,794 | 1,333 | 1,837 | Upgrade
|
| Selling, General & Admin | 573.48 | 236.67 | 249.75 | 227.3 | 182.83 | Upgrade
|
| Research & Development | 452 | 2 | 52 | 177.11 | 200.08 | Upgrade
|
| Amortization of Goodwill & Intangibles | - | - | - | 5.67 | 23 | Upgrade
|
| Operating Expenses | 1,115 | 238.67 | 301.75 | 410.08 | 405.91 | Upgrade
|
| Operating Income | 1,560 | 1,292 | 1,492 | 922.89 | 1,431 | Upgrade
|
| Interest Expense | -307.66 | -225.51 | -187.19 | -187.96 | -166.14 | Upgrade
|
| Interest & Investment Income | 33.59 | 47.34 | 72.29 | 78.34 | 53.54 | Upgrade
|
| Earnings From Equity Investments | 29.09 | 29.61 | 28.88 | -8.97 | -19.49 | Upgrade
|
| Other Non Operating Income (Expenses) | -14.35 | -7.53 | -24.03 | 81.86 | -27.21 | Upgrade
|
| EBT Excluding Unusual Items | 1,300 | 1,136 | 1,382 | 886.15 | 1,271 | Upgrade
|
| Gain (Loss) on Sale of Investments | 24.01 | 194.46 | 317.98 | -40.26 | -30.21 | Upgrade
|
| Asset Writedown | - | - | - | -615.83 | - | Upgrade
|
| Pretax Income | 1,324 | 1,331 | 1,700 | 230.06 | 1,241 | Upgrade
|
| Earnings From Continuing Operations | 1,324 | 1,331 | 1,700 | 230.06 | 1,241 | Upgrade
|
| Minority Interest in Earnings | -553.25 | -471.83 | -565.25 | -187.23 | -621.47 | Upgrade
|
| Net Income | 770.95 | 858.98 | 1,135 | 42.83 | 619.73 | Upgrade
|
| Net Income to Common | 770.95 | 858.98 | 1,135 | 42.83 | 619.73 | Upgrade
|
| Net Income Growth | -10.25% | -24.31% | 2549.50% | -93.09% | -36.44% | Upgrade
|
| Shares Outstanding (Basic) | 430 | 448 | 448 | 438 | 415 | Upgrade
|
| Shares Outstanding (Diluted) | 564 | 594 | 603 | 438 | 415 | Upgrade
|
| Shares Change (YoY) | -4.99% | -1.46% | 37.66% | 5.59% | 10.48% | Upgrade
|
| EPS (Basic) | 1.79 | 1.92 | 2.54 | 0.10 | 1.49 | Upgrade
|
| EPS (Diluted) | 1.78 | 1.91 | 2.53 | 0.10 | 1.49 | Upgrade
|
| EPS Growth | -6.83% | -24.54% | 2490.74% | -93.44% | 12.97% | Upgrade
|
| Dividend Per Share | 0.880 | 0.840 | 0.800 | 0.760 | 0.680 | Upgrade
|
| Dividend Growth | 4.76% | 5.00% | 5.26% | 11.77% | 126.67% | Upgrade
|
| Gross Margin | 112.44% | 67.64% | 76.19% | 59.58% | 80.22% | Upgrade
|
| Operating Margin | 65.58% | 57.10% | 63.37% | 41.25% | 62.49% | Upgrade
|
| Profit Margin | 32.42% | 37.95% | 48.20% | 1.92% | 27.07% | Upgrade
|
| EBITDA | 1,563 | - | 1,498 | 928.56 | 1,454 | Upgrade
|
| EBITDA Margin | 65.74% | - | 63.61% | 41.50% | 63.50% | Upgrade
|
| D&A For EBITDA | 3.85 | - | 5.67 | 5.67 | 23 | Upgrade
|
| EBIT | 1,560 | 1,292 | 1,492 | 922.89 | 1,431 | Upgrade
|
| EBIT Margin | 65.58% | 57.10% | 63.37% | 41.25% | 62.49% | Upgrade
|
| Revenue as Reported | 2,378 | 2,264 | 2,355 | 2,237 | 2,289 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.